Emily Salmini

[Nature Cell Biology] The authors identified a COTL1high natural killer subset that mediates immune checkpoint blockade responsiveness in patients with impaired tumour-specific major histocompatibility complex class I.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists profiled peripheral and central T cell responses in patients with multiple system atrophy (MSA), in comparison with Parkinson’s disease and healthy control cohorts. They demonstrated that peripheral T cells from MSA patients are activated and skewed toward cytotoxic and inflammatory phenotypes.

[Immunity] The authors discuss how aging shapes memory T cell compartments—from repertoire contraction and differentiation to altered metabolic, transcriptional, and epigenetic states.

[Trends In Immunology] Although traditionally viewed as rapid and potent innate effectors against infected or transformed cells, NK cells possess adaptive capabilities, such as antigen-specific clonal expansion and the generation of long-lived memory cells.

[University of Buffalo] The FDA has approved the immune checkpoint inhibitor nivolumab in combination with chemotherapy for adults and adolescents 12 and older with previously untreated Stage III/IV classic Hodgkin lymphoma.

[Cancer Immunology Research] Mammaglobin-A (Mam-A) is a tumor-associated antigen expressed in >50% of patients with breast cancer. To evaluate the potential of the Mam-A vaccine, researchers initiated a Phase Ib clinical trial in patients with ER+ breast cancer. Ex vivo enzyme-linked immunospot analysis of peripheral blood mononuclear cells demonstrated that vaccination induces Mam-A–specific T cells in 8 of 13 patients.